Trademarks, patents, copyright
Property rights over ideas that create the incentive to innovate.
The Constitution gave Congress the power to grant exclusive rights to inventions and creative works for limited times. The principle: without protection, innovators wouldn't recoup their investment, so they wouldn't innovate. With protection, they can charge enough to justify the R&D.
The system has trade-offs. Too short a term and innovators don't invest. Too long and society overpays for innovations that should have entered the public domain. Pharma patents work like this: the drug is expensive while the patent runs, then cheap as a generic afterward.
For operators, IP matters strategically. What IP do you own? What's enforceable? What's protected by trade-secret rather than patent? What expires when? The decisions cascade through pricing, competitive positioning, and acquisition strategy.
Examples in the wild
Many SaaS companies underuse IP protection. Their software is differentiated and protectable, but they don't file patents or properly trademark their brand. The legacy industries (pharma, chemicals, semis) are much more rigorous.
Companies whose moat is IP-based (pharma, chip designs, branded consumer goods) need explicit IP analysis. When the IP expires or weakens, the moat goes with it.
Creative work you do for others often defaults to their ownership unless you specify otherwise. Worth knowing before producing anything substantial under contract.
Trademarks, patents, copyright is one of the mental models we apply through real cases inside the Pareto MBA — a part-time program for professionals who want to think clearly about business.